In the management of diabetes insipidus, which agent is specifically used for central DI?

Desmopressin is the agent specifically used for the management of central diabetes insipidus (DI), a condition characterized by insufficient production of vasopressin (antidiuretic hormone) by the posterior pituitary. This synthetic analog of vasopressin effectively binds to the V2 receptors in the renal collecting ducts, promoting water reabsorption and thereby reducing urine output, which alleviates the symptoms of excessive thirst and urination associated with central DI.

In cases of central DI, the kidneys are functionally normal but are unable to concentrate urine due to the lack of vasopressin. Since desmopressin mimics the action of this hormone, it directly addresses the underlying deficiency, providing quick relief from symptoms.

While vasopressin itself could also be used to treat central DI due to its natural hormone role, desmopressin offers a more convenient and safer option with a lower risk of adverse effects, making it the preferred treatment. Indomethacin, a non-steroidal anti-inflammatory drug, can impact nephrogenic diabetes insipidus but is not used for treating central DI. Corticosteroids do not have a direct role in managing central DI and would not address the deficiency in